Lyell Immunopharma, Inc. Equity Securities, FV-NI, Unrealized Loss
Lyell Immunopharma, Inc. (LYEL) reported Equity Securities, FV-NI, Unrealized Loss of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2026-03-12
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2025-12-31 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2025-09-30 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2025-06-30 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2024 was $13.00M, a 0.60% increase from fiscal 2023.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2023 was $12.92M, a 158.46% increase from fiscal 2022.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2022 was $5.00M, a 86.28% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $13.00M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $13.00M 10-Q · filed 2025-11-12 | $13.00M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $13.00M 10-Q · filed 2025-08-12 | $13.00M derived: sum of 3 quarters · filed 2026-03-12 | $13.00M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $13.00M 10-Q · filed 2025-05-13 | $13.00M derived: sum of 2 quarters · filed 2026-03-12 | $13.00M derived: sum of 3 quarters · filed 2026-03-12 | $15.92M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $2.92M derived: sum of 3 quarters · filed 2026-03-12 | $12.92M 10-K · filed 2026-03-12 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $2.92M derived: sum of 2 quarters · filed 2024-11-07 | $12.92M 10-Q · filed 2024-11-07 | $12.92M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $2.92M 10-Q · filed 2024-08-07 | $12.92M 10-Q · filed 2024-08-07 | $12.92M derived: sum of 3 quarters · filed 2025-03-11 | $17.92M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $10.00M 10-Q · filed 2024-05-06 | $10.00M derived: sum of 2 quarters · filed 2025-03-11 | $15.00M derived: sum of 3 quarters · filed 2025-03-11 | $15.00M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.00M derived: sum of 2 quarters · filed 2025-03-11 | $5.00M derived: sum of 3 quarters · filed 2025-03-11 | $5.00M 10-K · filed 2025-03-11 |
| 2022-09-30 | $5.00M 10-Q · filed 2023-11-07 | $5.00M derived: sum of 2 quarters · filed 2023-11-07 | $5.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $36.45M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |